SAN FRANCISCO (MarketWatch) -- AstraZeneca PLC said Monday that results from a one-year study show that patients taking its Symbicort single-inhaler therapy had fewer asthma attacks and required less ...

MADISON, Wis.--(BUSINESS WIRE)--Propeller Health, a leading digital health company dedicated to the management of asthma and COPD, today announced it has received 510(k) clearance from the U.S. Food ...

AstraZeneca's Symbicort is racing toward patent expiration. But on Thursday, the company won six more months of exclusivity for the asthma and COPD inhaler. (Photo by Jonathan Ferrey/Getty Images) ...

If budesonide-formoterol were to become available over the counter (OTC) and used as-needed for mild asthma, it would save lives and cut healthcare costs, according to a computer modeling study ...

The victory marks the fourth Symbicort patent deemed invalid or not infringed in court, Viatris and Kindeva pointed out. (Viatris) In the courtroom fracas over the patents on AstraZeneca’s ...

AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.

Add Yahoo as a preferred source to see more of our stories on Google. Starting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price caps go into effect for the ...